You are here
...
The modular design presented at a ceremony in Marburg, Germany, consists of shipping containers fitted with the equipment necessary to make the company’s mRNA-based vaccine, save for the final step of putting doses into bottles, a process known as fill and finish.
“Our goal is to enable mRNA production on all continents,” BioNTech CEO Ugur Sahin told The Associated Press.
BioNTech has been criticized by some campaign groups for refusing to suspend its vaccine patents and let rivals manufacture the shots as part of an effort to make them more widely available, especially in poor countries. The company argues that the process of making mRNA vaccines is difficult and it prefers to work with local partners to ensure consistent quality of the shots worldwide. ...
Recent Comments